Surufatinib
Surufatinib Basic information
- Product Name:
- Surufatinib
- Synonyms:
-
- N-(2-(diMethylaMino)ethyl)-1-(3-((4-((2-Methyl-1H-indol-5-yl)oxy)pyriMidin-2-yl)aMino)phenyl)MethanesulfonaMide
- KDR-IN-1
- EOS-61498
- HMPL012
- HMPL-012
- HMPL-012;SURUFATINIB;HMPL012
- Surufatinib
- CS-2346
- CAS:
- 1308672-74-3
- MF:
- C24H28N6O3S
- MW:
- 480.58
- Mol File:
- 1308672-74-3.mol
Surufatinib Chemical Properties
- Boiling point:
- 712.9±70.0 °C(Predicted)
- Density
- 1.332±0.06 g/cm3(Predicted)
- storage temp.
- Store at -20°C
- solubility
- DMSO:98.0(Max Conc. mg/mL);203.92(Max Conc. mM)
- form
- A solid
- pka
- 5.22±0.40(Predicted)
- color
- White to off-white
- InChIKey
- TTZSNFLLYPYKIL-UHFFFAOYSA-N
- SMILES
- C1(CS(NCCN(C)C)(=O)=O)=CC=CC(NC2=NC=CC(OC3C=CC4=C(C=3)C=C(C)N4)=N2)=C1
Surufatinib Usage And Synthesis
Uses
Sulfatinib is used in pharmaceutical compositions comprising of micronized drug.
Mechanism of action
Surufatinib can inhibit multiple targets related to angiogenesis and tumor growth, including VEGFR, FGFR1 and CSF-1R.
Synthesis
Treatment of sulfonyl chloride 358 at room temperature using triethylamine and 2,2,2-trifluoroethanol (TFE) as solvents followed by hydrogenation afforded aniline 360. Exposure of 360 to DBU under microwave conditions generated an intermediate sulfinyl group. This intermediate sulfinyl group subsequently underwent nucleophilic attack by a commercial diamine, of which diamine 361 afforded the desired sulfonamide 362. Dichloropyrimidine 363 underwent a substitution reaction with hydroxyindole 364 to afford diaryl ether 365. Diaryl ether 365 then underwent a second substitution reaction with amine 362 under acidic conditions. Exposure of the product to a base in aqueous solution ultimately afforded surufatinib in 50% yield.
in vivo
In animal studies, a single oral dosing of Sulfatinib inhibits VEGF stimulated VEGFR2 phosphorylation in lung tissues of nude mice in an exposure-dependent manner. Furthermore, elevation of FGF23 levels in plasma 24 hours post dosing suggests suppression of FGFR signaling. Sulfatinib demonstrates potent tumor growth inhibition in multiple human xenograft models and decreases CD31 expression remarkably, suggesting strong inhibition on angiogenesis through VEGFR and FGFR signaling. In a syngeneic murine colon cancer model CT-26, Sulfatinib demonstrates moderate tumor growth inhibition after single agent treatment[1]. After oral dosing of 10 mg/kg, the AUC and Cmax are 397 ng/mL and 138ng/mL in the mouse, respectively[1].
IC 50
VEGFR1; VEGFR2; VEGFR3; FGFR1; CSF1R
SurufatinibSupplier
- Tel
- 010-88886666-01 13112345678
- loyson@tcypharm.com
- Tel
- nanfengdrug@163.com; 18616377689
- nanfengdrug@163.com
- Tel
- 021-58950125
- info@chemexpress.com
- Tel
- 13661494087 18964793018
- sales@mof-chemicals.com
- Tel
- 028-81700200 18116577057
- 3003855609@qq.com